

CONTACTS: Trace Longo
Longo Communications
(949) 364-2821
trace.longo@sbcglobal.net

Julia Hileman
Lumen Biomedical, Inc.
(763) 577-9600
hileman@lumenbio.com

**LUMEN BIOMEDICAL TO PRESENT EPIC CAROTID STENTING TRIAL AT
TCT CONFERENCE**

PLYMOUTH, MN & WASHINGTON D.C. – October 3, 2008 – Lumen Biomedical, Inc., a Minnesota-based medical device company, announced today that Co-Principal Investigator Subbarao V. Myla, M.D. will present the results from the EPIC clinical trial: *Evaluating the Use of the FiberNet® Embolic Protection Device in Carotid Artery Stenting*, during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, at the Washington Convention Center in Washington DC. The presentation is scheduled for Thursday, October 16, 2008 at 1 p.m. as part of “The Late Breaking First Report Investigations” taking place in the Main Arena. The press conference will take place on the 16th from 9:50-10:00 a.m. in room 159A.

ABOUT LUMEN BIOMEDICAL, INC.:

Lumen Biomedical is driven towards the development and commercialization of unique interventional devices for use in multiple anatomical areas where embolic protection or thrombus removal may be required. These markets include peripheral vascular and coronary applications with potentials approaching 1.6 billion worldwide. To learn more about Lumen Biomedical, Inc. visit the web site at www.lumenbio.com.

###